Skip to main content
Premium Trial:

Request an Annual Quote

Synthetic Biology Company Intrexon Raises $150M in Series F Preferred Investment Round

NEW YORK (GenomeWeb News) – Synthetic biology firm Intrexon said late Wednesday that it has closed a Series F preferred investment round that raised $150 million.

Proceeds from the financing round will be used for working capital to establish additional channel collaborations in the firm's core sectors, including healthcare, food, energy, and environment, it said, adding that funding will also be used for further development of its technology platforms and expansion of its sales and marketing and R&D efforts.

New investors accounted for the majority of funding in the round. Current investors, including affiliates of Intrexon Chairman and CEO Randal Kirk, as well as Third Security, also participated.

In total, the Germantown, Md.-based firm has raised $509 million, it said. About two years ago, it raised $100 million in a Series E round, and in January 2010 it raised $25 million.

"The Intrexon team is committed to delivering results for all of our collaborations," Kirk said in a statement. "With our proprietary technology platforms, we are helping our collaborators discover, design, develop, and ultimately bring to market genetically enhanced products that hold remarkable promise."

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.